title: [Risk factors in elderly patients selected by primary care physicians for hypolipemic treatment].
abstract: OBJECTIVE
  To evaluate the influence of age on response to pravastatin treatment in patients treated by community physicians.
  
  
  METHODS
  According to age, 873 patients were divided in three groups: group A with ages ranging from 45 to 59 years (n = 55), group B with ages from 60 to 64 years (n = 182) and group C with ages from 65 to 70 years (n = 143). After four weeks only with diet orientation, patients received 10 mg/day of pravastatin for 12 weeks.
  
  
  RESULTS
  There was a greater prevalence of risk factors in elderly patients: hypertension (45.7%, 54.4% and 57.1% in groups A, B and C respectively p = 0.0165), diabetes mellitus (9.3%, 17.6% and 25.8% respectively in groups A, B and C p < 0.0001), and previous heart disease (23.1%, 34.3% and 34.7% in groups A, B and C respectively p < 0.001). During the period of diet orientation there was a similar total cholesterol reduction in the three groups (about 10.5%), the reduction reached 30.0% with the introduction of pravastatin for 12 weeks. Low density cholesterol level decreased during the diet period in the three groups (about 10.5%), pravastatin prescription induced further reduction (about 31.7%). The high density cholesterol level (HDL) increased significantly with pravastatin treatment (12.7%). After pravastatin treatment the increase in HDL levels was more significantly among those patients with initial low levels of HDL (< 35 mg/dL) in the three groups.
  
  
  CONCLUSIONS
  In patients selected by community physicians to receive lipid lowering therapy, increased age was associated with greater prevalence of risk factors and heart disease. Regardless of age, there was a good response to pravastatin treatment, however less than half of patients had received treatment prior to the protocol.
authors.affiliation: Instituto do Coração do Hospital das Clínicas-FMUSP, São Paulo.
authors.forename: A C
authors.initials: AC
authors.lastname: Barretto
authors.forename: M
authors.initials: M
authors.lastname: Wajngarten
authors.forename: O C
authors.initials: OC
authors.lastname: Gebara
authors.forename: J B
authors.initials: JB
authors.lastname: do Serro Azul
authors.forename: H
authors.initials: H
authors.lastname: Pierri
authors.forename: A
authors.initials: A
authors.lastname: Nussbacher
authors.forename: L
authors.initials: L
authors.lastname: Pivotto
authors.forename: G
authors.initials: G
authors.lastname: Bellotti
authors.forename: F
authors.initials: F
authors.lastname: Pileggi
mesh_terms: D000367:Age Factors; D000368:Aged; D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D002784:Cholesterol / Q000097:blood; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000188:drug therapy* / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D017035:Pravastatin / Q000627:therapeutic use*; D012307:Risk Factors; D014280:Triglycerides / Q000097:blood
chemical_list: D000924:Anticholesteremic Agents; D014280:Triglycerides; D002784:Cholesterol; D017035:Pravastatin